DEPARTMENT OF HEALTH & HUMAN SERVICES



Food and Drug Administration Rockville MD 20857

FEB 2 \$ 2011

Re: Vimpat US Patent Nos.5,654,301 and RE38,551 New Drug Application 22-253 Docket Nos. FDA-2009-E-0172 FDA 2009-E-0174

The Honorable David J. Kappos
Under Secretary of Commerce for Intellectual Property
Director of the United States Patent and Trademark Office
Mail Stop Hatch-Waxman PTE
P.O. Box 1450Alexandria, VA 22313-1450

Dear Director Kappos:

This is in regard to the patent term extension applications for U.S. Patent Nos. 5,654,301 and RE38,551 filed by Research Corporation Technologies, Inc. under 35 U.S.C. § 156. The patents claim Vimpat (lacosamide), new drug application (NDA) 22-253.

In the April 23, 2010, issue of the <u>Federal Register</u> (75 Fed. Reg. 21298), the Food and Drug Administration published its determination of this product's regulatory review period, as required under 35 U.S.C. § 156(d)(2)(A). The notice provided that on or before October 20, 2010, 180 days after the publication of the determination, any interested person could file a petition with FDA under 35 U.S.C. § 156(d)(2)(B)(i) for a determination of whether the patent term extension applicant acted with due diligence during the regulatory review period.

The 180-day period for filing a due diligence petition pursuant to this notice has expired and FDA has received no such petition. Therefore, FDA considers the regulatory review period determination to be final.

Please let me know if we can provide further assistance.

Sincerely yours,

Jane A. Axelrad

Associate Director for Policy

Center for Drug Evaluation and Research

Jane a. afelis!

cc: Kevin G. Shaw

Hogan & Hartson, LLP 555 Thirteenth Street, NW Washington, DC 20004